其 他 安 全 警 示
|
| |
| The United Kingdom: Falsified Mounjaro KwikPen 15mg pre-filled pens (English only) |
| |
Medicines and Healthcare products Regulatory Agency (MHRA) announces that a falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection has been found supplied through one online pharmacy in the UK. The falsified product is labelled with batch D873576 and applies to Mounjaro KwikPen 15mg solution for injection in pre-filled pen only.
Eli Lilly and Company Limited has informed the MHRA that 5 falsified versions of Mounjaro (tirzepatide) KwikPen 15mg solution for injection in pre-filled pen have been identified to date, supplied by The Private Pharmacy Clinic, located in Birmingham, UK. The falsified pens are labelled as Mounjaro KwikPen 15mg solution for injection in pre-filled pen and have the batch number D873576. Please note that the expiry date of these products (10/26) is not relevant – check batch number and dose only. All pens identified to date have been faulty, often with a dose knob which comes off while in use. Eli Lilly and Company Limited have confirmed that the batch number and expiry date on the legitimate pack matches a genuine Mounjaro KwikPen 7.5mg solution for injection in pre-filled pen, whereas the falsified product packaging indicates that this product is Mounjaro KwikPen 15mg solution for injection in pre-filled pen.
Testing of the falsified pens that have been recovered confirmed that they do contain tirzepatide. However, because MHRA does not know how the pen has been manufactured, it cannot be sure that the pen is sterile. As this is an injectable product, if its contents are not sterile, there is potential for infection. Allergic reactions may also occur. If a patient believes they have used a falsified product, they should be assessed for signs and symptoms of infection or hypersensitivity reactions. The MHRA has not received any reports of patient harm that required treatment after taking this falsified medicine. Advice for healthcare professionals and patients as a precautionary measure who may be in possession of a 15mg pen with this batch number is provided in the MHRA website.
Mounjaro (tirzepatide) is a dual glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonist authorised for the treatment of type 2 diabetes mellitus and weight management in patients who are overweight or obese.
Please refer to the following website in MHRA for details:
http://www.gov.uk/drug-safety-update/falsified-mounjaro-kwikpen-15mg-pre-filled-pens
In Hong Kong, Mounjaro Kwikpen Solution For Injection In Pre-filled Pen 15mg/0.6ml (HK-68410) is a pharmaceutical product registered by Eli Lilly Asia, Inc. and is a prescription-only medicine. The pack of the falsified Mounjaro KwikPen referenced in the above MHRA’s announcement is different from the registered pack of the product in Hong Kong.
Ends/Wednesday, Feb 25, 2026
Issued at HKT 15:45
|
| |
